$4.49
0.14[3.22%]
Last update: 9:59AM Get Real Time Here
Ventyx Biosciences
(NASDAQ:VTYX)Ventyx Biosciences Stock (NASDAQ:VTYX), Analyst Ratings, Price Targets, Predictions
Ventyx Biosciences Inc has a consensus price target of $24.5, established from looking at the 42 latest analyst ratings. The last 3 analyst ratings were released from Canaccord Genuity, Oppenheimer, and Wells Fargo on March 13, 2024, March 12, 2024, and March 12, 2024. With an average price target of $14.33 between Canaccord Genuity, Oppenheimer, and Wells Fargo, there's an implied 246.22% upside for Ventyx Biosciences Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Canaccord Genuity
Oppenheimer
Wells Fargo
Stifel
Evercore ISI Group
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Ventyx Biosciences
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/13/2024 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 262.32% | Canaccord Genuity | Edward Nash | $16 → $15 | Maintains | Buy | Get Alert |
| 03/12/2024 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 189.86% | Oppenheimer | Jeff Jones | → $12 | Upgrade | Perform → Outperform | Get Alert |
| 03/12/2024 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 286.47% | Wells Fargo | Derek Archila | $7 → $16 | Upgrade | Equal-Weight → Overweight | Get Alert |
| 03/11/2024 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 286.47% | Canaccord Genuity | Edward Nash | $20 → $16 | Maintains | Buy | Get Alert |
| 02/21/2024 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | — | Oppenheimer | Jeff Jones | — | Reiterates | → Perform | Get Alert |
| 12/19/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | -27.54% | Wells Fargo | Derek Archila | $8 → $3 | Maintains | Equal-Weight | Get Alert |
| 12/18/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | -51.69% | Stifel | Alex Thompson | $6 → $2 | Maintains | Hold | Get Alert |
| 11/10/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 20.77% | Evercore ISI Group | Josh Schimmer | $43 → $5 | Downgrade | Outperform → In-Line | Get Alert |
| 11/07/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 44.93% | Morgan Stanley | Vikram Purohit | $46 → $6 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 11/07/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 44.93% | Stifel | Alex Thompson | → $6 | Downgrade | Buy → Hold | Get Alert |
| 11/07/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | — | HC Wainwright & Co. | Emily Bodnar | — | Downgrade | Buy → Neutral | Get Alert |
| 10/10/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 1252.66% | Stifel | Alex Thompson | → $56 | Reiterates | Buy → Buy | Get Alert |
| 10/10/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 1156.04% | HC Wainwright & Co. | Emily Bodnar | → $52 | Reiterates | Buy → Buy | Get Alert |
| 08/29/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 1011.11% | Morgan Stanley | Simon Flannery | $45 → $46 | Maintains | Overweight | Get Alert |
| 08/11/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 1397.58% | Credit Suisse | Tiago Fauth | $63 → $62 | Maintains | Outperform | Get Alert |
| 08/11/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 1156.04% | HC Wainwright & Co. | Emily Bodnar | $54 → $52 | Maintains | Buy | Get Alert |
| 07/05/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 1397.58% | Oppenheimer | Jeff Jones | → $62 | Reiterates | Outperform → Outperform | Get Alert |
| 07/05/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 1204.35% | HC Wainwright & Co. | Emily Bodnar | $54 → $54 | Reiterates | Buy → Buy | Get Alert |
| 06/14/2023 | VTYX | Buy Now | Ventyx Biosciences | $4.14 | 1421.74% | Credit Suisse | Tiago Fauth | → $63 | Assumes | → Outperform | Get Alert |
FAQ
What is the target price for Ventyx Biosciences (VTYX)?
The latest price target for Ventyx Biosciences (NASDAQ: VTYX) was reported by Canaccord Genuity on March 13, 2024. The analyst firm set a price target for $15.00 expecting VTYX to rise to within 12 months (a possible 234.08% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Ventyx Biosciences (VTYX)?
The latest analyst rating for Ventyx Biosciences (NASDAQ: VTYX) was provided by Canaccord Genuity, and Ventyx Biosciences maintained their buy rating.
When was the last upgrade for Ventyx Biosciences (VTYX)?
The last upgrade for Ventyx Biosciences Inc happened on March 12, 2024 when Oppenheimer raised their price target to $12. Oppenheimer previously had a perform for Ventyx Biosciences Inc.
When was the last downgrade for Ventyx Biosciences (VTYX)?
The last downgrade for Ventyx Biosciences Inc happened on November 10, 2023 when Evercore ISI Group changed their price target from $43 to $5 for Ventyx Biosciences Inc.
When is the next analyst rating going to be posted or updated for Ventyx Biosciences (VTYX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Ventyx Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Ventyx Biosciences was filed on March 13, 2024 so you should expect the next rating to be made available sometime around March 13, 2025.
Is the Analyst Rating Ventyx Biosciences (VTYX) correct?
While ratings are subjective and will change, the latest Ventyx Biosciences (VTYX) rating was a maintained with a price target of $16.00 to $15.00. The current price Ventyx Biosciences (VTYX) is trading at is $4.49, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.